News & Media

Recent updates from Arcutis.

May 22, 2025 Featured

Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older
Read More

July 9, 2024 Featured

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age
Read More

December 15, 2023 Featured

FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
Read More

June 6, 2025

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read More

June 6, 2025

Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference
Read More

June 2, 2025

NPF Expands Seal of Recognition to FDA-approved Treatments and Awards its First to Arcutis’ ZORYVE® (roflumilast)
Read More

May 29, 2025

Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
Read More

May 15, 2025

New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice
Read More

May 7, 2025

Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology
Read More

May 6, 2025

Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update
Read More

May 2, 2025

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read More

April 17, 2025

Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025
Read More

April 10, 2025

Arcutis Announces Chief Financial Officer Transition
Read More

April 4, 2025

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read More

Media Resources

Corporate Fact Sheet

Download

Uncovering Psoriasis

Download

Journal of the American Medical Association Roflumilast Cream 0.3% Result

Click Here

Media Contact

Amanda Sheldon

805.418.5006
media@arcutis.com

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download
You are leaving Arcutis.com.

This link will send you to a site maintained by an independent third party.
Arcutis is not responsible for the content on that site.

Cancel Continue